Sequence variations within the genes related to hemostatic imbalance and their impact on coronary artery disease in Turkish population

Thrombosis Research

Volumn 119, Issue 1, 2007, Pages 55-62

  Taymaz, Hilal ^a   Erarslan, Serpil ^b   Toksoy Öner, Ebru ^c   Alkan, Tijen ^d   Aǧirbaşli, Mehmet ^c   Kirdar, Betül ^a  

^a BOGAZICI UNIVERSITY   (Turkey)

^b Duzen Laboratories   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d VKV American Bristol Hospital   (Turkey)

Author keywords

Coagulation factors; Coronary artery disease; Polymorphisms; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL SIGNIFICANCE; THROMBOSIS; TURKEY (REPUBLIC);

ADULT; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DNA PRIMERS; FACTOR V; FACTOR VII; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; TURKEY;

EID: 33750807530     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.12.018     Document Type: Article

References (63)

1. Daley G.Q., and Cargill M. The heart SNPs a beat: polymorphisms in candidate genes for cardiovascular disease. Trends Cardiovasc Med 11 (2001) 60-66
2. Ng M.C.Y., Wang Y., So W.Y., Cheng S., Visvikis S., Zee R.Y.L., et al. Ethnic differences in the linkage disequilibrium and distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular diseases. Genomics 83 (2004) 559-565
3. Grant P.J., and Humphries S.E. Genetic determinants of arterial thrombosis. Baillieres Best Pract Res Clin Haematol 12 (1999) 505-532
4. Bernardi F., Marchetti G., Pinotti M., Arciere P., Baroncini C., Papacchini M., et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 16 (1996) 72-76
5. Wu A.H., and Tsongalis G.J. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 87 (2001) 1361-1366
6. Iacoviello L., Di Castelnuovo A., De Knijff P., D'Orazio A., Amore C., Arboretti R., et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 338 (1998) 79-85
7. Girelli D., Russo C., Ferraresi P., Olivieri O., Pinotti M., Friso S., et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 343 (2000) 774-780
8. Segev A., Ellis M.H., Segev F., Friedman Z., Reshef T., Sparkes J.D., et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol 98 (2005) 421-424
9. Middendorf K., Gohring P., Huehns T.Y., Seidel D., Steinbeck G., and Nikol S. Prevalence of resistance against activated protein C resulting from Factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Am Heart J 147 (2004) 897-904
10. Tosetto A., Missiaglia E., Frezzato M., and Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 82 (1999) 1395-1398
11. Kang S.S., Wong P.W., Susmano A., Sora J., Norusis M., and Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 48 (1991) 536-545
12. Engbersen A.M., Franken D.G., Boers G.H., Stevens E.M., Trijbels F.J., and Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 56 (1995) 142-150
13. Endler G., and Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 330 (2003) 31-55
14. Kim R.J., and Becker R.C. Association between Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146 (2003) 948-957
15. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., and Hennekens C.H. Endogenous type plasminogen activator and risk of myocardial infarction. Lancet 341 (1993) 1165-1168
16. Carter A.M., Catto A.J., and Grant P.J. Determinants of t-PA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb Haemost 80 (1998) 632-636
17. Sartoi M.T., Wiman B., Vettore S., Dazzi F., Girolami A., and Patrassi G.M. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 80 (1998) 956-960
18. Juhan-Vague I., Valadier J., Alessi M.C., Aillaud M.F., Anasaldi J., Philip-Joet C., et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 57 (1987) 67-72
19. Eriksson P., Kallin B., van'T Hooft F., Bavenholm P., and Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92 (1995) 1851-1855
20. Francis C.W. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 126 (2002) 1401-1404
21. Benes P., Muzik J., Benedik J., Frelich M., Elbl L., Vasku A., et al. Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male Caucasians. Mol Genet Metab 69 (2000) 137-143
22. Hooper W.C., Lally C., Austin H., Renshaw M., Dilley A., Wenger N.K., et al. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 99 (2000) 223-230
23. Iacoviello L., Burzotta F., Di Castelnuovo A., Zito F., Marchioli R., and Donati M.B. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 80 (1998) 1029-1030
24. Burzotta F., Di Castelnuovo A., Amore C., D'Orazio A., Donati M.B., and Iacoviello L. 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction in subjects over 45 years. Thromb Haemost 78 (1997) 1294-1295
25. Ossei-Gerning N., Mansfield M.W., Stickland M.H., Wilson I.J., and Grant P.J. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 17 (1997) 33-37
26. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., and Miletich J.P. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95 (1997) 59-62
27. Eriksson P., Kallin B., van't Hooft F.M., Bavenholm P., and Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92 (1995) 1851-1855
28. Ye S., Green F.R., Scarabin P.Y., Nicaud V., Bara L., Dawson S.J., et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 74 (1995) 837-841
29. Onat A., and Senocak M. Relative risk of factors for coronary heart disease in a population with low cholesterol levels. Int J Cardiol 43 (1994) 51-60
30. Mrozikiewicz P.M., Cascorbi I., Ziemer S., Laule M., Meisel C., Stangl V., et al. Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J Am Coll Cardiol 36 (2000) 1520-1525
31. Di Castelnuovo A., D'Orazio A., Amore C., Falanga A., Donati M.B., and Iacoviello L. The decanucleotide insertion/deletion polymorphism in the promoter region of the coagulation factor VII gene and the risk of familial myocardial infarction. Thromb Res 98 (2000) 9-17
32. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
33. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
34. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
35. Juul K., Tybjaerg-Hansen A., Steffensen R., Kofoed S., Jensen G., and Nordestgaard B.G. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 100 (2002) 3-10
36. Mansourati J., Da Costa A., Munier S., Mercier B., Tardy B., Ferec C., et al. Prevalence of Factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 83 (2000) 822-825
37. Van de Water N.S., French J.K., Lund M., Hyde T.A., White H.D., and Browett P.J. Prevalence of Factor V Leiden and prothrombin variant G20210A in patients age < 50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 36 (2000) 717-722
38. Lande G., Dantec V., Trossaert M., Godin J.F., and Le Marec H. Do inherited prothrombotic factors have a role in myocardial infarction with normal coronary arteriogram?. J Intern Med 244 (1998) 543-544
39. Rosendaal F.R., Siscovick D.S., Schwartz S.M., Beverly R.K., Psaty B.M., Longstreth Jr. W.T., et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89 (1997) 2817-2821
40. Rees D.C., Cox M., and Clegg J.B. World distribution of Factor V Leiden. Lancet 346 (1995) 1133-1134
41. Akar N., Akar E., Ozel D., Deda G., and Sipahi T. Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res 102 (2001) 115-120
42. Corral J., Gonzalez-Conejero R., Lozano M.L., Rivera J., and Vicente V. Genetic polymorphisms of factor VII are not associated with arterial thrombosis. Blood Coagul Fibrinolysis 9 (1998) 267-272
43. Heywood D.M., Ossei-Gerning N., and Grant P.J. Association of factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. Thromb Haemost 76 (1996) 161-165
44. Lane A., Green F., Scarabin P.Y., Nicaud V., Bara L., Humphries S., et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 119 (1996) 119-127
45. Franco R.F., Trip M.D., ten Cate H., van den Ende A., Prins M.H., Kastelein J.J., et al. The 20210 G/A mutation in the 3′untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 104 (1999) 50-54
46. Boekholdt S.M., Bijsterveld N.R., Moons A.H., Levi M., Buller R.J., and Peters R.J. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 104 (2001) 3063-3068
47. Gardemann A., Arsic T., Katz N., Tillmanns H., Hehrlein F.W., and Haberbosch W. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb Haemost 81 (1999) 208-213
48. Ridker P.M., Hennekens C.H., and Miletich J.P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99 (1999) 999-1004
49. Corral J., Gonzalez-Conejero R., Lozano M.L., Rivera J., Heras I., and Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 99 (1997) 304-307
50. Akar N., Misirlioglu M., Akar E., Avcu F., Yalcin A., and Sozuoz A. Prothrombin gene 20210 G-a mutation in the Turkish population. Am J Hematol 58 (1998) 249
51. Almawi W.Y., Ameen G., Tamim H., Finan R.R., and Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis 17 (2004) 199-205
52. Morita H., Taguchi J., Kurihara H., Kitaoka M., Kaneda H., Kurihara Y., et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95 (1997) 2032-2036
53. Jee S.H., Beaty T.H., Suh I., Yoon Y., and Appel L.J. The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 153 (2000) 161-168
54. Wilcken D.E., Wang X.L., Sim A.S., and McCredie R.M. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 16 (1996) 878-882
55. Ma J., Stampfer M.J., Henneken C.H., et al. Methylenetetrahydrofolatepolymorphism, plasma folate, homocysteine, and risk of infarction in US physicians. Circulation 98 (1998) 2510-2516
56. Rothenbacher D., Fischer H.G., Hoffmeister A., Hoffmann M.M., Marz W., Bode G., et al. Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis 162 (2002) 193-200
57. Zuntar I., Topic E., Vukosavic D., Vukovic V., Demarin V., Begonja A., et al. Croatian population data for the C677T polymorphism in methylenetetrahydrofolate reductase: frequencies in healthy and atherosclerotic study groups. Clin Chim Acta 335 (2003) 95-100
58. Kalina A., and Czeizel A.E. The methylenetetrahydrofolate reductase gene polymorphism (C677T) is associated with increased cardiovascular mortality in Hungary. Int J Cardiol 97 (2004) 333-334
59. Tokgozoglu S.L., Alikasifoglu M., Unsal, Atalar E., Aytemir K., Ozer N., et al. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 81 (1999) 518-522
60. Dilley A., Hooper W.C., El-Jamil M., Renshaw M., Wenger N.K., and Evatt B.L. Mutations in the genes regulating methylene tetrahydrofolate reductase (MTHFR C → T677) and cystathione beta-synthase (CBS G → A919, CBS T → c833) are not associated with myocardial infarction in African Americans. Thromb Res 103 (2001) 109-115
61. Abbate R., Sardi I., Pepe G., Marcucci R., Brunelli T., Prisco D., et al. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost 79 (1998) 727-730
62. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma. Its role in thrombotic disease. Thromb Haemost 74 (1995) 71-76
63. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745